NXP002 is our lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis
- Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation.
- Tranilast has a long history of safe use as an oral drug for allergies but there is evidence (widely published in peer reviewed scientific papers) that supports its potential in fibrosis, including IPF.
- Overall findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated extra-cellular matrix (ECM) protein production, a major therapeutic target in IPF, presenting it as a promising and novel anti-fibrotic agent.
Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.
